logo
Share SHARE
FONT-SIZE Plus   Neg

Lexicon Phase 2 Trial Of Anti-Tumor Drug Meets Primary Endpoint, Begins Phase 3

Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company announced new data from its recently completed Phase 2 study of its investigational drug telotristat etiprate for carcinoid tumors. Through the trial, the drug achieved its primary endpoint that is the reduction of bowel movements from baseline at week 12 in 46.4 percent of the patients involved in the study and suffering from metastatic carcinoid syndrome. In addition, the company said it would present the data from the trial at the North American Neuroendocrine Tumor Society on October 13 in California.

Further, the company added Telotristat etiprate, administered orally was well tolerated by the patients with only three of the patients reporting serious adverse events, none of which was related to study drug.

In a statement, the company said it is also initiating a 12-week registrational Phase 3 trail that is designed to test the drug's safety, efficacy after its positive outlook in the Phase 2 trials, said Lexicon in a statement.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ford Motor Co. has issued a safety recall for nearly 117,000 vehicles in North America to replace improperly tempered bolts in seats and seatbelts that could fracture. The affected vehicles include 2014 Ford F-150 pickup trucks, 2014 E-Series vans, 2014-15 Ford Escape SUVs and 2015 Lincoln MKC SUVs to replace improperly tempered bolts in seats and seatbelts. Electronics retailer Best Buy is adding Dyson mini-shops to its select stores in the U.S. next month. Dyson is a maker of vacuums, hair dryers, air purifiers and other household items. Starting in August, about 90 U.S. Best Buy stores will get new Dyson Demo Experiences - dedicated spaces that will enable customers try out Dyson products as if they were in their own home. Shares of Airbus Group SE were losing around 4 percent in the morning trading in Paris after the aerospace and defense major reported Thursday a sharp decline in its second-quarter profit with lower revenues. Further, the company maintained its guidance for the full year 2017.
comments powered by Disqus
Follow RTT